Concord Biotech Ltd. · NSE:CONCORDBIO
Concord Biotech — Q2 FY26 Earnings Presentation
30 slides from Concord Biotech's earnings presentation, Nov 13, 2025
Slide 1: Investor's Presentation filing letter to NSE and BSE
CONCORD BIOTECH LIMITED B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: complianceofficer@concordbiotech.com ------------------------------------------------------
Slide 2: Concord Biotech Limited Investor Presentation – November 2025
CONCORD BIOTECH Concord Biotech Limited Investor Presentation – November 2025
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Concord Biotech Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 4: Q2 & H1FY26 Key Financial Highlights
Q2 & H1FY26 Key Financial Highlights
Slide 5: Q2 & H1FY26 Key Highlights
Q2 & H1FY26 Key Highlights Regulatory Approvals for multiple sites ensuring business continuity and Key Developments – H1FY26 greater global market penetration Inspection by United States Food and Drug Administration (US FDA) Discussion with Innovators • Company has received an Establishment Inspect
Slide 6: Q2 & H1FY26 Key Highlights: Challenges and Mitigation
Q2 & H1FY26 Key Highlights Challenges Mitigation The renewal application for the Written Confirmation from Delay in renewal of Written the Central Drugs Standard Control Organization (CDSCO), We have now received the requisite approval on 4th Confirmation from CDSCO to New Delhi — a requirement for
Slide 7: Q2 & H1FY26 Consolidated Financial Highlights
Q2 & H1FY26 Consolidated Financial Highlights Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) Revenue impacted on account of • Delay in renewal of Written 526.0 218.0 155.3 451.1 149.9 107.1 Confirmation from CDSCO to 136.7 95.8 supply in European Union 310.2 247.1 63.1 88.5 • Delay in Sup
Slide 8: Q2 & H1FY26 Segment wise Revenue Split
Q2 & H1FY26 Segment wise Revenue Split API Revenue (Rs. in Crs) Formulation Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) 401.0 345.6 125.0 526.0 105.5 451.1 230.0 80.2 310.2 191.8 55.3 247.1 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26 H1FY25 H1FY26 API : Formulation (Q2F
Slide 9: Q2 & H1FY26 Geography wise Revenue Split
Q2 & H1FY26 Geography wise Revenue Split Domestic Revenue (Rs. in Crs) Exports Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) 292.3 233.6 526.0 204.1 451.1 246.9 145.8 310.2 164.4 121.1 247.1 126.0 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26 H1FY25 H1FY26 Q2FY25 Q2FY26 H1FY25 H1FY26 Domestic : Export
Slide 10: Management Commentary
Management Commentary Commenting on the Q2 & H1FY26 performance of the company Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer for Concord Biotech Limited said, Revenue for Q2 declined due to the postponement of sales caused by delays in receiving written renewal confirmation from
Slide 11: Q2 & H1FY26 Consolidated Profit & Loss Account
Q2 & H1FY26 Consolidated Profit & Loss Account Profit and Loss (Rs. in Crs) Q2FY26 Q2FY25 YoY Q1FY26 Q-o-Q H1FY26 H1FY25 YoY Revenue from Operations 247 310 -20% 204 21% 451 526 -14% Cost of Goods Sold 49 76 45 94 125 Gross Profit 198 234 -15% 159 25% 357 401 -11% Gross Profit Margin 80.2% 75.4% 77.
Slide 12: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (in Rs. Crs) Sept-25 Mar-25 Equity & Liabilities (in Rs. Crs) Sept-25 Mar-25 Non - Current Assets 943.3 899.0 Total Equity 1,826.8 1,812.7 Property Plant & Equipment's 786.6 791.8 Share Capital 10.5 10.5 CWIP 74.2 50.1 Other Equity 1,817.0 1,802.3 Intangible assets
Slide 13: Abridged Cashflow Statement
Abridged Cashflow Statement Particulars (in Rs. Crs) H1FY26 H1FY25 Net Profit Before Tax 144.42 209.86 Adjustments for: Non -Cash Items / Other Investment or Financial Items 11.67 16.86 Operating profit before working capital changes 156.09 226.72 Changes in working capital -56.88 18.20 Cash generat
Slide 14: Company Overview
Company Overview
Slide 15: Concord Biotech at a Glance
Concord Biotech at a Glance Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Key Highlights Expertise in ✓ Expertise in fermentation-based API manufacturing wit
Slide 16: Driving Innovation Through Our Expertise
Driving Innovation Through Our Expertise Fermentation Expertise Through our strong fermentation capabilities, we produce high-quality APIs, setting us apart in biotechnology and ensuring superior efficacy in medicines Mission Focus Dedicated to deliver high-quality product that enhance human health,
Slide 17: API Business Overview
API Business Overview API Overview One of the leading global developers and Focus on Niche Fermentation API’s with Diversified Product Portfolio of API’s including manufacturers of Fermentation-based APIs backward integration to Key Starting Material Immuno-suppressant, Oncology, Anti- Infectives &
Slide 18: Formulation Business Overview
Formulation Business Overview Formulation Overview Commercialization of Formulations business in Operate through B2B model across regulated Oral Solid Dosages (tablets, capsules and oral suspension) 2016 to capitalize on the benefits of backward and emerging markets Injectables (Liquid Vials, Dry Po
Slide 19: Trusted CDMO partner for Fermentation & Semi-Synthetic API's
Trusted CDMO partner for Fermentation & Semi-Synthetic API’s CDMO Overview Prioritizes innovation, backed by a DSIR- Expertise in fermentation technology and strong Provide contract research and manufacturing R&D infrastructure enable us to undertake complex certified R&D facility with a team of 180
Slide 20: Pushing Boundaries through Manufacturing Capabilities
Pushing Boundaries through Manufacturing Capabilities Unit I (API) – Dholka, Gujarat Unit II (Formulations) – Valthera, Gujarat FY2000 Operations commenced FY2016 Operations commenced 112302 sq.m. Spread across 94826 sq.m. Spread across 450 m3 Installed capacity 802Mn Units Installed capacity Unit I
Slide 21: Pioneering R&D Capabilities
Pioneering R&D Capabilities R&D Initiatives: State-of-the-Art Facilities: Where Ideas Materialise 180 7/5 R&D Employee Approved ANDA/ API R&DLab Strength Finished Products Cost Improvement • Specialized capabilities for isolation of strains, mutation, and passive selection of microbial strains, as w
Slide 22: DMF Filings Across Geographies
DMF Fillings Across Geographies Molecules US EU Canada Japan China Tacrolimus ✓ ✓ ✓ ✓ ✓ Mycophenolate Mofetil ✓ ✓ ✓ ✓ ✓ Suppressants Immuno- Mycophenolate Sodium ✓ ✓ ✓ ✓ Cyclosporine ✓ ✓ ✓ ✓ ✓ Sirolimus ✓ ✓ ✓ ✓ Pimecrolimus ✓ Voclosporin ✓ Temsirolimus ✓ ✓ Everolimus ✓ ✓ ✓ ✓ Oncology Romidepsin ✓ ✓
Slide 23: Wide Range of Formulation Product Portfolio for Overseas Markets
Wide Range of Formulation Product Portfolio for Overseas Markets Regulated Markets Emerging Markets Product Name ANDA Approval Product Name Mycophenolate Mofetil Capsules Mycophenolate Mofetil Capsules Mycophenolate Mofetil Tablets Mycophenolic Acid DR Tablets USP Mycophenolate Mofetil Suspension My
Slide 24: Diversified Customer Base
Diversified Customer Base New Customer Addition / Product Addition in Existing Customers 118 95 63 47 FY22 FY23 FY24 FY25 Reducing Customer Concentration % Contribution from Top 10 Customers 35.8% FY25 70+ Countries 42.0% FY24 FY23 44.3% Worldwide Presence Tailored Distribution Models 47.7% FY22 250
Slide 25: Paving the Way for Sustainability
Paving the Way for Sustainability Our Vision for Sustainability The Path of Sustainability Sustainable Manufacturing Research & Development Efficient Resource Management Global Green Leadership Constant Improvement & Adaptation Environmental Conservation Awarded Bronze Medal by EcoVadis Our Initiati
Slide 26: Key Business Differentiators
Key Business Differentiators
Slide 27: End-to-End Expertise in Complex Fermentation Value Chain
End-to-End Expertise in Complex Fermentation Value Chain Overview of Integrated Platform Leadership Position 1250 M3 Leadership position for select molecules Fermentation Capacity across two in global markets API facilities R&D Patents 01 02 03 04 Key Starting Material API Manufacturing Over 2 Decad
Slide 28: Constructing Formidable Barriers to Entry
Constructing Formidable Barriers to Entry Significant Capital Intensive Operational Complex Process & Infrastructural Requirements Long gestation Period Entry Barriers Technical Expertise Requirements (large scale fermenters) Complex technical capabilities, difficulties in scaling up operations and
Slide 29: Key Growth Drivers
Key Growth Drivers API Business Expanding API Marketing existing APIs Increasing wallet share Portfolio to new customers with existing customers 01 Formulations Business CONCORD BIOTECH Expanding portfolio through own development & in- Launching new dosage forms including Expanding geographic reach
Slide 30: For further Information, please contact
For further Information, please contact Company: Investor Relations Advisor: Concord Biotech Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24230GJ1984PLC007440 CIN - U74140MH2010PTC204285 Mr. Lalit Sethi – Chief Financial Officer lalitsethi@concordbiotech.com Mr. Sagar Shroff / Mr. Vatsal Shah s